MTOR inhibitor-based combination therapies for pancreatic cancer

Creative Commons License

Hassan Z., Schneeweis C., Wirth M., Veltkamp C., Dantes Z., Feuerecker B., ...Daha Fazla

BRITISH JOURNAL OF CANCER, cilt.118, sa.3, ss.366-377, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 118 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1038/bjc.2017.421
  • Dergi Adı: BRITISH JOURNAL OF CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.366-377
  • Anahtar Kelimeler: MTOR, pancreatic cancer, therapeutic resistance, IN-VIVO, DUCTAL ADENOCARCINOMAS, FEEDBACK ACTIVATION, PRECLINICAL MODELS, CELL PLASTICITY, ONCOGENIC KRAS, LUNG-CANCER, TUMORIGENESIS, RESISTANCE, EGFR
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs further clarification.